Cargando…

Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity

BACKGROUND: Older age at organ transplantation is associated with increased risk of infection and malignancy but reduced risk of cellular rejection. De novo donor-specific anti-HLA antibodies (dnDSA), are key biomarkers associated with reduced long-term allograft survival, yet there is a lack of dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Moos, Seraina, Schalk, Gesa, Mueller, Thomas F., Laube, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509825/ https://www.ncbi.nlm.nih.gov/pubmed/31168309 http://dx.doi.org/10.1186/s12979-019-0149-8

Ejemplares similares

Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center study
por: Shah, Sadia Z., et al.
Publicado: (2022)

Criterion Validity and Test-Retest Reliability of a Modified Version of the International Physical Activity Questionnaire–Short Form (IPAQ-SF) in Kidney Transplant Recipients
por: Kohlbrenner, Dario, et al.
Publicado: (2022)

Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
por: Park, Woo Yeong, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Mycophenolic Acid Identifies Kidney Transplant Recipients Responsive to Two SARS-CoV-2 mRNA Vaccine Doses
por: von Moos, Seraina, et al.
Publicado: (2023)

De Novo Cytomegalovirus Colitis in a Donor-Seronegative/Recipient-Seronegative Kidney Transplant Recipient
por: Sulaiman, Zoheb I, et al.
Publicado: (2023)

Cancer among kidney transplant recipients >20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term
por: Fuhrmann, Julia D, et al.
Publicado: (2022)

Role of de novo DQ donor-specific antibody in antibody-mediated rejection in renal transplant recipient: A case study
por: Chowdhry, Mohit, et al.
Publicado: (2019)

Assessment of Organ Quality in Kidney Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet
por: von Moos, Seraina, et al.
Publicado: (2020)

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
por: O'Leary, Jacqueline G., et al.
Publicado: (2016)

Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients
por: Yazawa, Masahiko, et al.
Publicado: (2019)

PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies
por: Spitznagel, Tahm, et al.
Publicado: (2022)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients
por: Song, Seung Hwan, et al.
Publicado: (2015)

Donor Noradrenaline Support Is Not Associated with Decreased Survival in Heart Transplant Recipients
por: Oehler, Daniel, et al.
Publicado: (2022)

Transplanting cells from old but not young donors causes physical dysfunction in older recipients
por: Wang, Binsheng, et al.
Publicado: (2020)

Collaboration between local nephrologists and the transplant centre ensures good outcomes in post-transplant care
por: Kaufmann, Yves L, et al.
Publicado: (2022)

Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience
por: Waldecker, Christoph B., et al.
Publicado: (2021)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation
por: Meneghini, Maria, et al.
Publicado: (2021)

Circulating de novo Donor Specific Antibodies and Carotid Intima-media Thickness in Pediatric Kidney Transplant Recipients, A Pilot Study
por: Sgambat, Kristen, et al.
Publicado: (2020)

De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
por: Cioni, Michela, et al.
Publicado: (2017)

A curious case of de novo anti-HLA-C antibody-mediated humoral rejection and Fabry-like zebra bodies in a renal transplant recipient
por: Abuzeineh, Mohammad, et al.
Publicado: (2020)

Clinical Outcome of Kidney Transplant Recipients with C1q-Binding De Novo Donor Specific Antibodies: A Single-Center Experience
por: Marinaki, Smaragdi, et al.
Publicado: (2023)

Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients
por: Cuffel, Alexis, et al.
Publicado: (2022)

COVID-19 in orthotopic heart transplant recipients and association with donor specific antibodies
por: Yang, Bin Q., et al.
Publicado: (2022)

Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2018)

Antithymocyte globulin is associated with a lower incidence of de novo donor‐specific antibody detection in lung transplant recipients: A single‐center experience
por: Narula, Tathagat, et al.
Publicado: (2021)

Combined Analysis of HLA Class II Eplet Mismatch and Tacrolimus Levels for the Prediction of De Novo Donor Specific Antibody Development in Kidney Transplant Recipients
por: Lee, Hyeyoung, et al.
Publicado: (2022)

Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
por: Warzyszyńska, Karola, et al.
Publicado: (2022)

Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients
por: Jordan, Stanley C., et al.
Publicado: (2018)

Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation
por: Lionaki, Sophia, et al.
Publicado: (2013)

The natural history of de novo donor-specific HLA antibodies after kidney transplantation
por: López del Moral, Covadonga, et al.
Publicado: (2022)

Post-transplant outcomes in recipients of living donor kidneys and intended recipients of living donor kidneys
por: Dharia, Atit A., et al.
Publicado: (2022)

Living Donor Kidney Transplant in Recipients With Glomerulonephritis: Donor Recipient Biologic Relationship and Allograft Outcomes
por: El-Rifai, Rasha, et al.
Publicado: (2023)

Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Adult Living-Donor Kidney Transplantation, Donor Age, and Donor–Recipient Age
por: Hiramitsu, Takahisa, et al.
Publicado: (2021)

De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction?
por: Alberu, Josefina, et al.
Publicado: (2012)

Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies
por: Kim, Jon Jin, et al.
Publicado: (2017)

Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk
por: Baghai Arassi, Maral, et al.
Publicado: (2022)

Impact of Resolved Preformed, Persistent Preformed, and De Novo Anti-HLA Donor-Specific Antibodies in Kidney Transplant Recipients on Long-Term Renal Graft Outcomes
por: Gniewkiewicz, Michal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4a26l2aqu5g5vrnfdgvcsh8pme